BZYR licenses antineoplaston patents from CEO; research funding secured through Feb 2024

BURZYNSKI RESEARCH INSTITUTE INC

License from Dr. Burzynski for exclusive rights to four US patents and pending applications for antineoplastons in US/Canada.
Research Funding Agreement: Dr. Burzynski funds all basic research and FDA-related trial costs; term to Feb 2024, auto-renewable.
Amended Royalty and Research Funding Agreements limited to US/Canada scope.
License can terminate if Burzynski removed as officer/director or if another party equals his voting power.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.